Progress in the international development of biotechnology medicines
DU Hai-zhou
LIU Gui-ling
WANG Tian-jin
LIU Na
L(U) Ting
CAO Yong-mei
Abstract：We reviewed product category and therapeutic category,outlined the status quo of development of biotechnology medicines,and briefly induced the 633 new biotechnology medicines internationally developed to treat various diseases in 2008. We especially emphasized the new biotechnology medicines, such as those to treat asthma, autoimmune diseases, HIV/AIDs,infectious diseases,skin disorders and blood disorders. Compared with the 418 new biotechnology medicines developed in 2006, the number of the biotechnology medicines has increased greatly (by 51.44%) in 2008. Based on the comparison and analysis,the conclusion is that monoclonal antibodies (MAbs) count a higher percentage in the biotechnology medicines developed internationally,which are used to treat cancer, autoimmune disorders, respiratory diseases, cardiovascular diseases, HIV/AIDs and blood disorders. The bio-technology medicines for cancer, infectious diseases, HIV/AIDs and cardiovascular diseases count for 74.06% (534/721)/76.37% (737/965) in 2008. They will be the main direction in development of biotechnology medi-cines in the future few years.
Keywords：biotechnology medicinesnew drugsinternational
Publication Date：2009-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：13( 2118-2130 )